PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901550
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1901550
The Digital Pathology Market size was valued at US$ 1,456.45 Million in 2024, expanding at a CAGR of 13.8% from 2025 to 2032.
The digital pathology market is growing rapidly as hospitals, laboratories, and pharmaceutical companies shift from glass slides to whole-slide imaging, cloud platforms, and AI-driven analysis. Adoption is driven by rising cancer cases, demand for faster and more accurate diagnostics, and the need for remote pathology and workflow efficiency. Advanced scanners, image management software, and AI algorithms enable high-resolution slide digitisation, quantitative biomarker analysis, and real-time collaboration. Pharmaceutical and biotech companies increasingly use digital pathology for drug discovery, clinical trials, and biomarker development. Strong investments, regulatory approvals, and expanding telepathology networks are accelerating global uptake. North America leads the market, while Asia-Pacific shows the fastest growth due to expanding healthcare infrastructure. However, High initial costs for scanners, software, and IT slow digital pathology adoption in smaller labs and cost-sensitive healthcare systems, hindering the market growth.
Digital Pathology Market- Market Dynamics
Rising global cancer incidence
As cancer cases grow, pathology labs face higher volumes of tissue samples requiring rapid, accurate interpretation. For instance, the report published in February 2024 by the World Health Organisation (WHO) stated that, in 2022, there were about 20 million new cancer cases and 9.7 million deaths worldwide. An estimated 53.5 million people were alive within five years of a cancer diagnosis. Roughly 1 in 5 people develop cancer, and about 1 in 9 men and 1 in 12 women die from it. However, traditional microscopy with glass slides often limits scalability, slows workflows, and depends heavily on manual review. Digital pathology addresses these challenges by converting glass slides into high-resolution whole-slide images that can be analysed, shared, and stored more efficiently. This allows pathologists to work faster, collaborate remotely with subspecialists, and deliver more consistent diagnoses. Thus, the growing global cancer incidence is one of the strongest forces accelerating the adoption of digital pathology, as healthcare systems worldwide struggle to manage increasing diagnostic workloads.
The Global Digital Pathology Market is segmented on the basis of Product, Type, Application, End-user, and Region.
The market is divided into four categories based on Product: Hardware, Software, Storage Systems, and Others. Among these, hardware, particularly scanners, holds the largest share, as it underpins digital pathology by enabling slide digitisation. Software is the fastest-growing segment due to rising adoption of AI-based image analysis, workflow management, and remote viewing platforms. Storage systems are becoming increasingly important because whole-slide images require massive, secure, long-term data storage. The other category includes services, peripherals, and communication infrastructure that support implementation and maintenance.
The market is divided into two categories based on Type: Human Pathology and Veterinary Pathology. In human pathology, digital tools support faster cancer diagnosis, AI-assisted slide analysis, remote reporting, and improved workflow efficiency in hospitals and diagnostic labs. Veterinary pathology uses digital platforms for livestock disease surveillance, companion-animal diagnostics, and research, helping improve herd health and reduce outbreak risks.
Digital Pathology Market- Geographical Insights
North America dominates the market due to the presence of advanced healthcare infrastructure, high adoption of digital solutions, and strong investments in research and development. Europe follows, supported by government funding, growing awareness of telepathology, and robust healthcare systems in countries like Germany, the U.K., and France. Asia-Pacific is emerging as a high-growth region owing to increasing healthcare expenditure, expanding hospital networks, and rising incidences of cancer and infectious diseases in countries such as China, India, and Japan. Government initiatives, such as the data published in September 2025 by the Press Bureau of India (PIB), India launched the IVD validation portal and VRDL Bulletin for viral tracking. This initiative further support the adoption of digital pathology for faster diagnostics. Latin America and the Middle East & Africa show moderate growth, driven by gradual digital adoption, awareness programs, and increasing private healthcare investments.
Digital Pathology Market- Country Insights
The United States is one of the largest and fastest-growing markets for digital pathology, supported by strong healthcare infrastructure, early technology adoption, and a high burden of chronic disease, especially cancer. For instance, in December 2025, the U.S. Department of Health and Human Services (HHS) unveiled its AI Strategy, marking the subsequent stage of its transformative effort to deploy artificial intelligence (AI) throughout the federal workforce, embedding it into internal operations, research endeavours, and public health initiatives. Moreover, the integration of cloud-based storage and high-resolution imaging solutions enables pathologists to remotely analyse and share slides, improving workflow efficiency. Rising demand for personalised medicine and precision diagnostics also fuels investment in digital pathology technologies.
The digital pathology market is moderately consolidated, with a mix of large diagnostics and imaging companies, dedicated digital pathology specialists, and emerging AI-focused startups shaping competition. Large diversified healthcare companies such as Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Leica Biosystems (Danaher Corporation) and others dominate scanners, imaging platforms, and enterprise software, leveraging existing hospital relationships and regulatory experience. On the other hand, specialised digital pathology firms compete on workflow-centric software, cloud deployment, and flexible integrations with LIS/EHR systems. Furthermore, AI-native companies focus on image analysis algorithms for cancer grading, quantification, and decision support, increasingly partnering with scanner and platform vendors rather than competing on hardware. Strategic moves include collaborations between AI developers and established imaging vendors, M&A to expand portfolios, and regional partnerships. For instance, in January 2025, Leica Biosystems announced that it enhanced its Aperio GT 450 digital pathology scanner in January 2025 with several workflow- and image-quality-oriented features, including DICOM-compatible output at both 20x and 40x magnification.
In April 2025, Visiopharm A/S partnered with another company (Indica Labs) to integrate the company's discovery image analysis tools into Indica's HALO Link platform, helping build a tailored digital pathology ecosystem for research and advanced image analytics.
In March 2023, Hamamatsu (NanoZoomer slide scanner line) was incorporated into a broader, open end-to-end digital pathology solution via partnership with Agilent and Visiopharm, aiming to support flexible, future-proof pathology workflows.